MX2016012403A - Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano. - Google Patents
Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.Info
- Publication number
- MX2016012403A MX2016012403A MX2016012403A MX2016012403A MX2016012403A MX 2016012403 A MX2016012403 A MX 2016012403A MX 2016012403 A MX2016012403 A MX 2016012403A MX 2016012403 A MX2016012403 A MX 2016012403A MX 2016012403 A MX2016012403 A MX 2016012403A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- receptor
- bind human
- human cannabinoid
- cannabinoid
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 2
- 239000003557 cannabinoid Substances 0.000 title abstract 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000008484 agonism Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente invención se refiere a anticuerpos y fragmentos de estos novedosos que se unen al receptor cannabinoide 1 (CB1). Los anticuerpos y fragmentos de estos descritos en la presente incluyen anticuerpos humanizados que se unen al receptor CB1. La invención también incluye los usos de los anticuerpos para tratar una enfermedad o trastorno que responde al antagonismo o agonismo del receptor CB1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014074199 | 2014-03-27 | ||
CN2014081797 | 2014-07-08 | ||
PCT/US2015/023108 WO2015148984A2 (en) | 2014-03-27 | 2015-03-27 | Antibodies that bind human cannabinoid 1 (cb1) receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016012403A true MX2016012403A (es) | 2017-06-14 |
Family
ID=53008849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016012403A MX2016012403A (es) | 2014-03-27 | 2015-03-27 | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano. |
Country Status (18)
Country | Link |
---|---|
US (3) | US10308712B2 (es) |
EP (2) | EP4159761A1 (es) |
JP (1) | JP6598844B2 (es) |
KR (2) | KR20230119670A (es) |
CN (1) | CN106232626B (es) |
AU (1) | AU2015237275B2 (es) |
BR (1) | BR112016022381A2 (es) |
CA (1) | CA2944049A1 (es) |
CL (3) | CL2016002433A1 (es) |
ES (1) | ES2915101T3 (es) |
IL (1) | IL248006B1 (es) |
MA (1) | MA39708A (es) |
MX (1) | MX2016012403A (es) |
NZ (1) | NZ724870A (es) |
PE (1) | PE20170258A1 (es) |
RU (1) | RU2730674C2 (es) |
TW (1) | TWI694086B (es) |
WO (1) | WO2015148984A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018003982A (es) * | 2015-09-30 | 2019-01-31 | Bird Rock Bio Inc | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano. |
AU2018282094A1 (en) | 2017-06-05 | 2019-12-12 | Janssen Biotech, Inc. | Antibodies that specifically bind PD-1 and methods of use |
CN110914430B (zh) | 2017-07-13 | 2023-11-21 | 协和麒麟株式会社 | 抗bril抗体以及使用了该抗体的bril融合蛋白质的稳定化方法 |
CN108588071A (zh) * | 2018-04-25 | 2018-09-28 | 和元生物技术(上海)股份有限公司 | CRISPR-Cas9靶向敲除人肠癌细胞CNR1基因及其特异性的sgRNA |
AR114436A1 (es) | 2018-04-30 | 2020-09-02 | Takeda Pharmaceuticals Co | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas |
EP3823610A4 (en) * | 2018-07-17 | 2022-08-31 | The Regents of the University of California | METHODS OF TREATMENT OF KIDNEY DISEASE |
EP3996747A4 (en) * | 2019-07-11 | 2023-08-16 | Tavotek Biotherapeutics (Hong Kong) Limited | AGENTS INTERFERING WITH THYMUS TROMIC LYMPHOPOIETIN (TSLP) RECEPTOR SIGNALING |
WO2023196770A2 (en) * | 2022-04-04 | 2023-10-12 | Bird Rock Bio, Inc. | Prediction and treatment of fast progressing renal disease |
WO2023234406A1 (ja) * | 2022-06-03 | 2023-12-07 | 塩野義製薬株式会社 | カンナビノイド1型受容体に結合する抗体 |
WO2024022478A1 (zh) * | 2022-07-28 | 2024-02-01 | 长春金赛药业有限责任公司 | 结合大麻素受体cb1的抗体及其用途 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466579A (en) | 1987-12-28 | 1995-11-14 | Psychemedics Corporation | Hair analysis method |
US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5817766A (en) | 1995-04-05 | 1998-10-06 | Roche Diagnostic Systems, Inc. | Reagents for a cannabinoid immunoassay |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
JP2007527389A (ja) * | 2003-06-30 | 2007-09-27 | メルク エンド カムパニー インコーポレーテッド | 放射性カンナビノイド−1受容体修飾因子 |
US20050095674A1 (en) | 2003-07-23 | 2005-05-05 | Lewis Deborah L. | Cannabinoid receptor interacting proteins and methods of use |
WO2005023232A2 (en) * | 2003-09-04 | 2005-03-17 | Affibody Ab | Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
ITMI20041033A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
WO2006047417A2 (en) | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
CA2609783A1 (en) | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7833260B2 (en) | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
WO2008048648A2 (en) * | 2006-10-17 | 2008-04-24 | Acadia Pharmaceuticals Inc. | Cb1-modulating compounds and their use |
RU2470021C2 (ru) | 2007-05-23 | 2012-12-20 | Мерк Шарп Энд Домэ Корп. | Пиридилпиперидиновые антагонисты рецептора орексинов |
KR101649189B1 (ko) | 2008-05-09 | 2016-08-18 | 애브비 인코포레이티드 | 최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도 |
FI20085579A0 (fi) | 2008-06-12 | 2008-06-12 | Valtion Teknillinen | Kannabiskäytön toteaminen |
IT1394400B1 (it) | 2009-02-25 | 2012-06-15 | Neuroscienze Pharmaness S C Ar L | Composizioni farmaceutiche |
EP2419447B1 (en) | 2009-04-17 | 2017-08-23 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
BR112013000841A2 (pt) * | 2010-07-15 | 2016-06-07 | Oleg Lliich Epshtein | composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano. |
WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
US9441033B2 (en) | 2011-02-14 | 2016-09-13 | Randox Laboratories Limited | Detection of synthetic cannabinoids |
US9435817B2 (en) | 2011-02-14 | 2016-09-06 | Randox Laboratories Limited | Detection of synthetic cannabinoids |
GB201102544D0 (en) | 2011-02-14 | 2011-03-30 | Randox Lab Ltd | Assay |
SI2709631T1 (sl) | 2011-05-20 | 2017-07-31 | INSERM -Institut National de la Sante et de la Recherche Medicale | Antagonisti receptorja cb1 |
US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
EP2698383B1 (en) | 2012-08-14 | 2020-11-25 | Randox Laboratories Ltd. | Detection of synthetic Cannabinoids |
EP3013860B1 (en) | 2013-06-26 | 2018-12-12 | Amgen Inc. | Cb1 receptor antigen-binding proteins and uses thereof |
KR20160097336A (ko) | 2013-12-12 | 2016-08-17 | 스템센트알엑스 인코포레이티드 | 신규 항-dpep3 항체 및 이의 사용 방법 |
-
2015
- 2015-03-27 TW TW104110160A patent/TWI694086B/zh active
- 2015-03-27 CA CA2944049A patent/CA2944049A1/en active Pending
- 2015-03-27 IL IL248006A patent/IL248006B1/en unknown
- 2015-03-27 EP EP22160342.6A patent/EP4159761A1/en active Pending
- 2015-03-27 MX MX2016012403A patent/MX2016012403A/es unknown
- 2015-03-27 ES ES15719033T patent/ES2915101T3/es active Active
- 2015-03-27 NZ NZ724870A patent/NZ724870A/en unknown
- 2015-03-27 BR BR112016022381A patent/BR112016022381A2/pt active Search and Examination
- 2015-03-27 JP JP2017502946A patent/JP6598844B2/ja active Active
- 2015-03-27 CN CN201580015645.5A patent/CN106232626B/zh active Active
- 2015-03-27 AU AU2015237275A patent/AU2015237275B2/en active Active
- 2015-03-27 PE PE2016001719A patent/PE20170258A1/es unknown
- 2015-03-27 US US14/774,582 patent/US10308712B2/en active Active
- 2015-03-27 EP EP15719033.1A patent/EP3122780B1/en active Active
- 2015-03-27 WO PCT/US2015/023108 patent/WO2015148984A2/en active Application Filing
- 2015-03-27 KR KR1020237022858A patent/KR20230119670A/ko not_active Application Discontinuation
- 2015-03-27 RU RU2016141919A patent/RU2730674C2/ru active
- 2015-03-27 KR KR1020167029997A patent/KR102553870B1/ko active IP Right Grant
- 2015-03-27 MA MA039708A patent/MA39708A/fr unknown
-
2016
- 2016-09-27 CL CL2016002433A patent/CL2016002433A1/es unknown
-
2019
- 2019-01-25 US US16/257,511 patent/US11566069B2/en active Active
- 2019-03-27 CL CL2019000799A patent/CL2019000799A1/es unknown
-
2021
- 2021-10-08 CL CL2021002637A patent/CL2021002637A1/es unknown
-
2023
- 2023-01-27 US US18/160,745 patent/US20230348589A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ724870A (en) | Antibodies that bind human cannabinoid 1 (cb1) receptor | |
MX2018003982A (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano. | |
GEP20227440B (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
PH12017501522B1 (en) | Antibodies to tau and uses thereof | |
PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
MX2017003247A (es) | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
PH12019502694A1 (en) | Anti-trkb antibodies | |
EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
MX2022000317A (es) | Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5. | |
ZA201606523B (en) | Antibodies that bind human cannabinoid 1 (cb1) receptor | |
MX2019002349A (es) | Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control. |